Poland· PL-100482918
Akeega
A poly (adp-ribose) polymerase (parp) inhibitors product containing niraparibum + abirateroni acetas, registered in Poland by Janssen-Cilag International N.V..
Checked against URPL (Poland) on
Informational only — not a medical device.
The record
At a glance
URPL (Poland)- Active substance
- Niraparibum + Abirateroni acetas
- Manufacturer
- Janssen-Cilag International N.V.
- Country
- Poland (PL)
- ATC code
- L01XK
- ATC class
- Poly (ADP-ribose) polymerase (PARP) inhibitors
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 2
- gtin05413868122459
- gtin03400930271247
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Niraparibum + abirateroni acetas in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesAKEEGAJanssen Biotech, Inc.
- SwitzerlandAkeega
- CzechiaAKEEGAJanssen-Cilag International N.V., Beerse
- SpainAKEEGA 100 MG/500 MG COMPRIMIDOS RECUBIERTOS CON PELICULAJanssen-Cilag International N.V
- FinlandAkeegaJanssen-Cilag International NV
- SwedenAkeega 100 mg/500 mg Filmdragerad tablettJanssen-Cilag International NV
- CanadaAKEEGAJANSSEN INC
- United KingdomAkeega 100mg/500mg tabletsJanssen-Cilag Ltd
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Akeega
- Liechtenstein · Akeega
- Norway · Akeega
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/11d1da14-aa88-4200-a0db-8f1e8e0a4495 GET /v1/drugs/11d1da14-aa88-4200-a0db-8f1e8e0a4495?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki powlekane",
"source": "urpl",
"strength": "100 mg/500 mg",
"packaging": "05413868122459 ¦ Rpz ¦ EU/1/23/1722/002 ¦ 150047\n56 tabl.\n¦ UR/Z/4c/116/23 - 03400930271247",
"substance": "Niraparibum 100 mg + Abirateroni acetas 446 mg",
"common_name": "Niraparibum + Abirateroni acetas",
"pl_product_id": "100482918",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about niraparibum + abirateroni acetas.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.